Latest from City of Hope

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.
 
Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses the factors that contribute to disparities in the treatment of patients with lung cancer.
 
Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.
Dan J. Raz, MD, MAS, co-director, Lung Cancer and Thoracic Oncology Program, assistant professor, Division of Thoracic Surgery, Department of Surgery, City of Hope, discusses the subsets of the ALCHEMIST trial.
Jae Y. Kim, MD, chief, Division of Thoracic Surgery, Department of Surgery, assistant professor, Department of Surgery, City of Hope, discusses the use of immune checkpoint inhibitors in surgical patients with lung cancer.
Erminia Massarelli, MD, PhD, MS, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the adoption of alectinib (Alecensa) as the first-line therapy in the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).
Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses disparities in the treatment of lung cancer.
 
Jae Y. Kim, MD, discusses developments with checkpoint inhibition in patients with resectable NSCLC.
Publication Bottom Border
Border Publication
x